CBF and cognitive evaluation of Alzheimer type patients before and after IMAO-B treatment: a pilot study

Eur Neuropsychopharmacol. 1992 Mar;2(1):31-5. doi: 10.1016/0924-977x(92)90033-5.


Ten patients diagnosed as affected by primary degenerative dementia of the Alzheimer type, with a mild to moderate cognitive and behavioral impairment, were studied in a double blind design when taking for 60 days 5 mg twice a day of L-deprenyl or placebo. Cognitive functions and cerebral blood flow were assessed at the beginning and at the end of treatment by a wide array of memory, attention, and language efficiency measures and by SPECT-99TcHMPAO procedure. Reduced CBF on the parietal lobes was demonstrated in the patients at baseline together with a reduction of memory and cognitive efficiency. At the end of the treatment patients who received L-deprenyl showed an improvement in cognitive efficiency and no changes in CBF, while patients treated with placebo showed a worsening of cognitive efficiency and further reduction of parietal lobe CBF.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / physiopathology
  • Alzheimer Disease / psychology
  • Attention / drug effects
  • Cerebrovascular Circulation / drug effects*
  • Cognition / drug effects*
  • Double-Blind Method
  • Female
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Memory / drug effects
  • Monoamine Oxidase Inhibitors / therapeutic use*
  • Selegiline / pharmacology
  • Selegiline / therapeutic use
  • Tomography, Emission-Computed, Single-Photon


  • Monoamine Oxidase Inhibitors
  • Selegiline